New Path for Melanoma Detection and Treatment Uncovered

New technique developed can detect circulating tumor cells (CTCs) that could provide a new avenue for cancer diagnosis and therapies. The findings of the study are published in the journal British Journal of Cancer.// This work builds on the continued success of the Melanoma Research Group, who developed the world's first blood test capable of detecting melanoma in its early stages.

Lead researcher Associate Professor Elin Gray said this new step was the first study to comprehensively describe the immense diversity found in melanoma CTCs.

"These preliminary findings are the first step towards a new way to stop melanoma from spreading around the body," Professor Gray said.

"If we can find a way to detect these cells reliably, then we have a chance to stop melanoma in its tracks with a powerful diagnostic tool and perhaps opportunities for therapies in the future."

Like a needle in a haystack

Until now Melanoma CTCs have proved to be incredibly elusive, with detection rates wildly varying from 40 to 87 percent.

Professor Gray said this ECU-led research has explained why CTCs have been so hard to find.

"We now understand that CTC detection cannot be resolved with a one-size-fits-all approach," she said.

"There is a huge amount of variety in the shape and bioactivity of these CTCs, and so they all look different and respond differently to assay tests. "To complicate things further, melanoma CTCs are hidden among thousands of other cells and matter in the blood. Within one milliliter of blood, there are often fewer than ten cancer cells among one billion red cells and one million white blood cells.

"It is much like finding a needle in a haystack."

A new approach

Armed with a better understanding of the complexity of the task, the researchers tried a multifaceted approach to detecting melanoma CTCs.

"By combining three assays together, we raised detection rates to 72 percent, which was a significantly and consistently higher result than using one test," Dr. Gray said.

"We are confident this approach is a move towards the reliable detection of CTCs, but we now need to tweak the assay to include a better combination to capture the broadest range of CTCs."

The ECU Melanoma Research Group is now working with artificial intelligence experts to fast-track the identification of CTCs.

Source-Eurekalert